Meta-analysis of observational studies of full-length and B-domain-deleted factor VIII for prophylaxis - A standard statistical approach [4]

Haemophilia

Volumn 9, Issue 6, 2003, Pages 748-750

  Gruppo, Ralph A ^a   Brown, D ^b,d   Wilkes, M M ^c   Navickis, R J ^c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

^c Hygeia Associates   (United States)

^d Gulf States Hemophilia and Thrombophilia Center   (United States)

Author keywords

Factor VIII; Haemophilia A; Haemorrhage; Half life; Meta analysis; Protein engineering

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8;

BLEEDING; CALCULATION; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFICACY; DRUG HALF LIFE; EVIDENCE BASED MEDICINE; GENE DELETION; HEMOSTASIS; HUMAN; INCIDENCE; LETTER; MEDICAL DECISION MAKING; META ANALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN DOMAIN; REGRESSION ANALYSIS; RISK FACTOR; STATISTICAL ANALYSIS;

EID: 0346957435     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2003.00834.x     Document Type: Letter

References (19)

1. Gruppo RA, Brown D, Wilkes MM, Navickis RJ. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis - a meta-analysis. Haemophilia 2003; 9: 251-60.
2. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12.
3. Ebell MH. Prearrest predictors of survival following in-hospital cardiopulmonary resuscitation: a meta-analysis. J Fam Pract 1992; 34: 551-8.
4. Shank WA Jr, Balducci L. Recombinant hemopoietic growth factors: comparative hemopoietic response in younger and older subjects. J Am Geriatr Soc 1992; 40: 151-4.
5. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994; 89: 635-41.
6. Linn FH, Rinkel GJ, Algra A, van Gijn J. Incidence of subarachnoid hemorrhage: role of region, year, and rate of computed tomography: a meta-analysis. Stroke 1996; 27: 625-9.
7. Shea JA, Healey MJ, Berlin JA, Clarke JR, Malet PF, Staroscik RN et al. Mortality and complications associated with laparoscopic cholecystectomy. A meta-analysis. Ann Surg 1996; 224: 609-20.
8. Raaymakers TV, Rinkel GJ, Limburg M, Algra A. Mortality and morbidity of surgery for unruptured intracranial aneurysms: a meta-analysis. Stroke 1998; 29: 1531-8.
9. Kanters SD, Banga JD, Stolk RP, Algra A. Incidence and determinants of mortality and cardiovascular events in diabetes mellitus: a meta-analysis. Vasc Med 1999; 4: 67-75.
10. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865-72.
11. Klijn CJ, Kappelle LJ, Algra A, van Gijn J. Outcome in patients with symptomatic occlusion of the internal carotid artery or intracranial arterial lesions: a meta-analysis of the role of baseline characteristics and type of antithrombotic treatment. Cerebrovasc Dis 2001; 12: 228-34.
12. Sandhu MS, White IR, McPherson K. Systematic review of the prospective cohort studies on meat consumption and colorectal cancer risk: a meta-analytical approach. Cancer Epidemiol Biomarkers Prev 2001; 10: 439-46.
13. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999; 18: 2693-708.
14. Centers for Disease Control and Prevention. Report on the Universal Data Collection Program. Atlanta, Georgia, USA: U.S. Department of Health and Human Services, 2002; 4(1): 1-28.
15. Lau J, Ioannidis JP, Schmid CH. Summing up evidence: one answer is not always enough. Lancet 1998; 351: 123-7.
16. Berlin JA. Benefits of heterogeneity in meta-analysis of data from epidemiologic studies. Am J Epidemiol 1995; 142: 383-7.
17. Miners AH, Sabin CA, Tolley KH, Lee CA. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. J Intern Med 1998; 244: 515-22.
18. Yee TT, Beeton K, Griffioen A, Harrington C, Miners A, Lee CA, Brown SA. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 2002; 8: 76-82.
19. Hanna WT, Zimmerman CE. Lack of adequate bleed prevention and FVIII activity recovery with Refacto®: a series of case studies in hemophilia A patients. Blood 2001; 98: 531a.